– Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – – Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark…
Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a phase 3 study, potentially clearing the way for regulatory approval,
September 2, 2024